Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MDGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDGLMadrigal Pharmaceuticals$424.98-1.1%$414.50$200.63▼$463.63$9.44B-1.02369,973 shs43,385 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDGLMadrigal Pharmaceuticals0.00%-3.03%-0.61%+34.30%+100.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDGLMadrigal Pharmaceuticals$424.98-1.1%$414.50$200.63▼$463.63$9.44B-1.02369,973 shs43,385 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDGLMadrigal Pharmaceuticals0.00%-3.03%-0.61%+34.30%+100.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMDGLMadrigal Pharmaceuticals 2.73Moderate Buy$525.8823.74% UpsideCurrent Analyst Ratings BreakdownLatest MDGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/10/2025MDGLMadrigal PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$500.00 ➝ $590.0010/8/2025MDGLMadrigal PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/29/2025MDGLMadrigal PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$460.00 ➝ $560.009/27/2025MDGLMadrigal PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/12/2025MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$428.00 ➝ $526.009/4/2025MDGLMadrigal PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$500.008/26/2025MDGLMadrigal PharmaceuticalsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/26/2025MDGLMadrigal PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$390.00 ➝ $554.008/20/2025MDGLMadrigal PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$483.00 ➝ $485.008/12/2025MDGLMadrigal PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$458.00 ➝ $523.00(Data available from 10/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMDGLMadrigal Pharmaceuticals$515.55M18.30N/AN/A$34.59 per share12.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMDGLMadrigal Pharmaceuticals-$465.89M-$12.85N/AN/AN/A-54.68%-38.38%-27.32%10/30/2025 (Estimated)Latest MDGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/30/2025Q3 2025MDGLMadrigal Pharmaceuticals-$2.01N/AN/AN/A$244.33 millionN/A8/5/2025Q2 2025MDGLMadrigal Pharmaceuticals-$3.48-$1.90+$1.58-$1.90$158.94 million$212.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMDGLMadrigal Pharmaceuticals0.175.114.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMDGLMadrigal Pharmaceuticals98.50%Insider OwnershipCompanyInsider OwnershipMDGLMadrigal Pharmaceuticals21.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMDGLMadrigal Pharmaceuticals9022.20 million17.43 millionOptionableMDGL HeadlinesRecent News About These CompaniesSivik Global Healthcare LLC Acquires New Holdings in Madrigal Pharmaceuticals, Inc. $MDGLOctober 12 at 5:12 AM | marketbeat.comOppenheimer Maintains Madrigal Pharmaceuticals (MDGL) Outperform RecommendationOctober 11 at 3:49 AM | msn.comWealth Enhancement Advisory Services LLC Acquires New Shares in Madrigal Pharmaceuticals, Inc. $MDGLOctober 11 at 3:06 AM | marketbeat.comMadrigal Pharmaceuticals price target raised to $590 from $500 at OppenheimerOctober 10 at 12:43 PM | msn.comWeiss Ratings Reiterates "Sell (D-)" Rating for Madrigal Pharmaceuticals (NASDAQ:MDGL)October 10 at 7:50 AM | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOctober 9, 2025 | marketbeat.comMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)October 7, 2025 | globenewswire.comKnights of Columbus Asset Advisors LLC Increases Stock Position in Madrigal Pharmaceuticals, Inc. $MDGLOctober 7, 2025 | marketbeat.comStrid Group LLC Buys Shares of 2,500 Madrigal Pharmaceuticals, Inc. $MDGLOctober 5, 2025 | marketbeat.comJ. Safra Sarasin Holding AG Increases Holdings in Madrigal Pharmaceuticals, Inc. $MDGLOctober 4, 2025 | marketbeat.comQ3 Earnings Forecast for MDGL Issued By B. RileyOctober 4, 2025 | americanbankingnews.comWhat is B. Riley's Forecast for MDGL Q3 Earnings?October 2, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. $MDGL Holdings Decreased by AMI Asset Management CorpOctober 2, 2025 | marketbeat.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Sets New 1-Year High Following Analyst UpgradeOctober 2, 2025 | americanbankingnews.comMadrigal Pharmaceuticals price target raised to $560 from $460 at B. RileyOctober 1, 2025 | msn.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Hits New 52-Week High After Analyst UpgradeSeptember 30, 2025 | marketbeat.comMadrigal Pharmaceuticals: Rezdiffra's US And EU Rollout Remains PromisingSeptember 30, 2025 | seekingalpha.comB. Riley Securities Maintains Madrigal Pharmaceuticals (MDGL) Buy RecommendationSeptember 30, 2025 | msn.comA Glimpse Into The Expert Outlook On Madrigal Pharmaceuticals Through 7 AnalystsSeptember 29, 2025 | benzinga.comB. Riley Issues Positive Forecast for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock PriceSeptember 29, 2025 | marketbeat.comMadrigal Pharmaceuticals (MDGL) Gets a Buy from UBSSeptember 26, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDGL Company DescriptionsMadrigal Pharmaceuticals NASDAQ:MDGL$424.98 -4.62 (-1.08%) As of 11:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Microsoft 365 Premium Marks the Next Phase of AI Monetization 3 Reasons to Buy Sprouts Farmers Market Ahead of Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
